The next generation biopharmaceuticals

Affibody AB and GE Healthcare Expands its Relationship in the Field of Large-scale Affinity Purification

2011-09-09

Affibody and GE Healthcare today signed an agreement that will give GE Healthcare access to novel and proprietary technology that has been invented by Affibody in the field of large-scale affinity purification.

”It is exciting to announce that we continue our relationship with GE Healthcare who is the market leader within this field. “, says David Bejker, President and CEO of Affibody.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report Q2 (August 23, 2018)